Shamburg News · 8-K filed Nov 12, 2026, 4:16 PM EST
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
RNA · Atrium Therapeutics, Inc.
- Earnings
- Financing
- Materiality: high
Atrium Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, with collaboration revenue of $15.3 million and a net loss of $4.3 million, or $0.25 per share. The company reported pro-forma cash of $293.6 million as of September 30, 2026, including a $15.0 million BMS milestone and net proceeds from a $50.0 million private placement closed in October. The company said the cash is expected to fund operations through 2028.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458459.
Written from the filing by Shamburg Markets. Figures are as reported by the company.